Efficacy of Venetoclax Combined with Azacitidine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Objective To explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of patients with refractory and relapsed acute myeloid leukemia(R/R AML).Methods A retrospective analysis was conducted on 19 R/R AML patients admitted to the Department of Hematology of Taihe Hospital,Hubei University of Medicine from October 2020 to January 2024,to evaluate the therapeutic efficacy and safety of this regimen.Results After one course of treat-ment,the complete remission(CR)with with incomplete count recovery(CRi)rate was 68.42%,and the objective remis-sion rate(ORR)was 73.68%.Patients with CR/CRi had higher recurrence and mutations of NPM1,CEBPA,and TET2 than those with non-CR/CRi(all P＜0.05).The median follow-up time was 321 d among the 19 R/R AML patients,with a median overall survival(OS)of 287 d.Patients with CR/CRi had improved survival compared with those with non-CR/CRi(P＜0.05).Hematological adverse reactions,particularly anemia,were common,with the prevalence of anemia≥grade 3 being 52.63%.Among non-hematological adverse reactions,gram-positive bacterial pneumonia was the most com-mon(52.63%).Conclusion Venetoclax combined with azacitidine is an effective and safe treatment option for R/R AML patients,with high remission.Mutations of NPM1,CEBPA,and TET2 serve as potential markers for predicting therapeutic outcomes in patients.
万方数据
维普
